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Abstract: Background. Carotenoids and docosahexaenoic acid (DHA) were identified as essential
components for eye health and are both naturally present in eggs. Objective. We aimed to evaluate the
effect of the daily consumption of two eggs enriched with lutein/zeaxanthin and DHA on macular
pigment optical density (MPOD) and on circulating xanthophyll and fatty acid concentrations in
healthy participants. Methods. Ninety-nine healthy volunteers consumed either two standard eggs or
two enriched eggs per day for 4 months. MPOD was measured at baseline (V0) and at follow-up (V4)
using a modified confocal scanning laser ophthalmoscope (primary outcome). Blood samples were
collected to determine total plasma and lipoprotein fatty acids and lutein/zeaxanthin compositions
at V0 and V4 (secondary outcomes). Results. A slight but significant increase in MPOD was observed
for all study participants consuming two eggs per day for 4 months at all eccentricities (0.5◦, 1◦, 2◦,
and 4◦). Plasma and lipoprotein lutein, zeaxanthin, and DHA concentrations significantly increased
in both groups but were greater in the enriched group (for the enriched group (V0 vs. V4): lutein,
167 vs. 369 ng/mL; zeaxanthin, 17.7 vs. 29.2 ng/mL; DHA, 1.89 vs. 2.56% of total fatty acids).
Interestingly, lutein from high-density lipoprotein (HDL) was strongly correlated with MPOD at 0.5
and 1◦ eccentricities (rho = 0.385, p = 0.008, and rho = 0.461, p = 0.001, respectively). Conclusions.
MPOD was slightly increased in both groups. Lutein, zeaxanthin, and DHA plasma concentrations
were strongly enhanced in the enriched group compared with the standard group. A significant
correlation was found between MPOD level and lutein concentration in HDL.
Keywords: enriched egg; lutein; docosahexaenoic acid (DHA); age-related macular degeneration
(AMD); macular pigment; microalgae; xanthophylls
1. Introduction
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss
affecting people over age 50 in Western countries [1]. Although the understanding of AMD
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pathogenesis is progressing rapidly, this disease is not totally understood. Epidemiological
studies have reported that the highest dietary intakes of vitamins C and E, zinc, lutein,
zeaxanthin, and long chain omega-3 polyunsaturated fatty acids (PUFAs), such as docosa-
hexaenoic acid (DHA), are associated with the greatest reduction in the risk of developing
early [2–5] and advanced AMD [6,7].
As primary constituents of macular pigment, carotenoids lutein and zeaxanthin are
believed to play crucial roles in maintaining the morphological and functional integrity of
the retina and, more specifically, of the macula [8]. Carotenoids have antioxidant properties
and act as filters for blue light [9,10]. They may thus protect the macula against light-
induced oxidative damage, which has been implicated in the pathogenesis of AMD [11].
DHA is a fatty acid found in high quantities in the retina, especially in photoreceptor
outer segments [12]. In vitro and in vivo studies on animals have shown that DHA plays
multiple functions in photoreceptors, including a structural role in membranes and specific
interactions with rhodopsin protein, which suggests that DHA influences visual trans-
duction processes [13]. Moreover, DHA is the precursor of oxygenated mediators that
display anti-inflammatory and anti-apoptotic properties [14]. The results of animal studies
of chronic deficiencies in DHA are in concordance with the crucial roles played by this fatty
acid in retinal functionality and retinal cell integrity [15–17].
Previous observations in humans and animals have shown that xanthophylls such
as lutein and zeaxanthin are delivered to tissues after being transported primarily by
high-density lipoproteins (HDLs) [18,19]. Given that dietary DHA increases plasmatic
HDL concentrations [20,21], clinical interventions hypothesizing that DHA would promote
xanthophyll transport to the retina have been carried out [22–24]. Thanks to its design,
only the study of Johnson and collaborators definitely demonstrated that adding DHA
to a lutein-rich supplement enhances plasma lutein concentration and macular pigment
optical density (MPOD), which is an indirect estimate of xanthophyll concentration in the
retina. However, while the authors measured the proportions of the different lipoprotein
subclasses, their effective enrichment in DHA and lutein was not investigated.
The objective of the present work was to evaluate the effects of adding DHA to
lutein and zeaxanthin supplementation on MPOD and on the composition of total plasma
and plasma lipoproteins in healthy participants. Moreover, we hypothesized that low
amounts of xanthophylls and DHA could increase MPOD using eggs, which are known
to increase nutrient bioavailability due to their phospholipid content [25], as a vector for
supplementation. Finally, the last novelty of this study is the use of Schizochitrium sp.
microalgae and alfalfa protein concentrate as a source of DHA and lutein, respectively, to
enrich hens’ eggs to increase lutein and DHA intake and thus potentially improve macular
pigment density.
2. Materials and Methods
2.1. Ethics Statements and Selection of Participants
All the participants gave their written consent after being informed about the purpose,
methodology, and potential risks of the study. This experiment was conducted in the
clinical center of the Institut Pasteur de Lille in accordance with the guidelines of the
Declaration of Helsinki of 1975 as revised in 1983, and the experiment was approved by
the local ethics committee (CPP Nord Ouest IV, CHU Lille, Lille, France, study number:
11/31, accepted on 3 May 2011). This study was registered at the French agency for the
safety of health products (Agence Nationale de Sécurité du Médicament et des Produits de
Santé, ANSM) under the number 2011-A00364-37 and at clinicaltrials.gov as NCT01480700
(available online: https://clinicaltrials.gov/ accessed on 23 September 2021).
One hundred twenty-five nonsmoking healthy men and women with a BMI ≤ 30 kg/m2
aged 18 to 55 years were screened, and ninety-nine were enrolled in the study (Figure 1).
Participants with hypolipemic treatment, total cholesterol > 2.5 g/L, triglycerides > 2.0 g/L,
diabetes, cardiovascular disease, currently evolving disease (cancer, neurodegenerative
disease, etc.), or ocular disorders (maculopathy, optical neuropathy, cataract, anomalies
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in color vision, and corrected visual acuity of less than 8/10) were not included in the
study. Other exclusion criteria were the high consumption of carotenoids (more than
4 servings per week of foods rich in carotenoids), omega-3 fatty acids, or phytosterols
(through dietary supplement or diet—e.g., consumption of oily fish 4 times a week or
more, regular consumption of Danacol®-Danone, Rueil-Malmaison, France-or pro-activ’
margarine®-Unilever, Asnières sur Seine, France-) during the last 3 months, and known
hypersensitivity or allergy to eggs.
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2.2.1. St y y e a bjectives
This study as a onocenter, double-blind (participants and experi ental staff ere
blind), rando ized trial designed to investigate the effect of the consumption of eggs
enriched with lutein and DHA on macular pigment optical density (pri ary outco e).
Blood concentrations of xanthophylls and fatty acids were also investigated as secondary
outcomes. The random allocation sequence was generated by a biostatistician using blocks
of 4 and considering both egg composition and first eye performing MPOD analyses.
Medical staff enrolled the participants and assigned their randomization in order of their
arrival (signed consent).
2.2.2. Eggs
Study participants were asked to consume 2 eggs per day for 4 months. These eggs
were either standard eggs or enriched eggs with lutein and DHA. To improve compliance
and to favor meal diversification, participants were provided with a book containing more
than 100 recipes using eggs, which was especially developed for the study by a dietician.
No further recommendation was made on the way to consume the eggs.
The eggs were obtained from laying hens fed either a standard diet or a diet enriched
with lutein and DHA at the experimental farm of MIXSCIENCE (Sourches, France). Lutein
in the hens’ diet originated from alfalfa protein concentrate, whereas DHA was provided
by Schizochytrium sp. microalgae produced by ROQUETTE (Lestrem, France). The lutein
and DHA contents per egg were 0.12 mg and 37.6 mg for standard eggs and 0.96 mg and
134.4 mg for enriched eggs, respectively. The carotenoid, lipophilic vitamin, and polyun-
saturated fatty acid compositions of the eggs are described in Table 1. The composition of
standard eggs in this study was comparable with that of other standard eggs in the French
market [26,27].
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Table 1. Lutein, zeaxanthin, vitamin A, vitamin E, and polyunsaturated fatty acid contents of the eggs used in the study.
Nutrient
Concentration per Egg Concentration for Two Eggs
Standard Enriched p-Value Standard Group Enriched Group
Lutein, mean (SD), mg 0.120 (0.013) * 0.961 (0.142) * 1.64 × 10−5 0.24 1.922
Zeaxanthin, mean (SD), mg 0.065 (0.009) * 0.100 (0.012) * 2.06 × 10−5 0.13 0.2
DHA, mean (SD), mg 37.6 (6.5) * 134. 5 (14.7) * 1.64 × 10−5 75.3 268.9
EPA, mean, mg - - - - -
LA, mean, mg 479.9 440. 8 - 959.9 881. 6
ALA, mean, mg 11.2 45.2 - 22.3 90.4
Vitamin A, mean (SD), µg 0.178 0.224 - 0.356 0.448
Vitamin E, mean (SD), µg 1.40 1.57 - 2.8 3.14
Abbreviations: ALA = alpha-linolenic acid, DHA = docosahexaenoic acid, EPA = eicosapentaenoic acid, LA = linolenic acid, SD = standard
deviation. * n = 13, statistical analyses were performed using paired t tests. For other values, no statistical test was performed.
2.2.3. Dietary Recommendations
Before starting the study, the participants were asked to record in a food intake ques-
tionnaire all food ingested over seven days to determine dietary patterns and estimate
energy and macronutrient and micronutrient intakes. The same questionnaire was com-
pleted by the participants during the week preceding the end of the study. The food intake
questionnaire was completed by participants each day (or after each meal if possible)
for 7 days (paper completion). Each food intake questionnaire was verified by a trained
dietician using suvimax photography. Participants were asked not to change their dietary
habits during the study (except for eggs consumption), to consume no egg other than
those proposed in the study, and to remove all foods rich in lutein (cabbage, spinach,
flaxseed, etc.), phytosterols (Danacol® -Danone, Rueil-Malmaison, France-, pro-activ’®
margarine—Unilever, Asnières sur Seine, France- etc.), and DHA (oily fish such as sardine,
mackerel, salmon, etc.) from their diet. No specific egg cooking guidelines were given,
as egg preparation methods had no effects on egg lutein and DHA availability [26,27].
However, a book especially developed for the study with cooking recipes and advice was
given to participants in the two groups.
2.3. Blood Samples
Blood sample collection was conducted after overnight fasting before the start (V0)
and at the end of the 4-month intervention period (V4). Blood samples were collected
into tubes without additive for serum lipid analyses (V0 and V4) and into EDTA-coated
tubes for the separation of plasma, nucleated cells, and erythrocytes (V0 and V4). Samples
destined for lipid analyses were maintained at room temperature for at least 30 min to
allow clotting and were then centrifuged at a low speed of 1300× g for 10 min at 20 ◦C to
isolate serum. Serum total cholesterol, HDL cholesterol, and triglyceride concentrations
were determined by automaton (AU400, Olympus Medical, Hamburg, Germany) using an
enzymatic colorimetric method. Serum LDL concentrations were determined according to
the Friedewald calculation. EDTA-coated tubes were centrifuged at 1800× g for 10 min
at 4 ◦C to isolate plasma, nucleated cells, and erythrocytes. These samples were stored
at −80 ◦C until further analyses. LDL and HDL fractions were isolated from plasma
by sequential ultracentrifugation [28] using a Beckman ultracentrifuge (TLA-100.4 rotor,
543,000× g (100,000 rpm), +10 ◦C). Fraction protein content was measured using a Lowry
assay.
2.4. Determination of Plasma Lipoprotein and Erythrocyte Membrane Fatty Acids
All chemical reagents were purchased from Sigma-Aldrich (St Quentin, Fallavier,
France), and chloroform and methanol were purchased from SDS (Peypin, France). Total
lipids were extracted from total plasma, erythrocytes, and LDL- and HDL-fractions ac-
cording to Moilanen and Nikkari [29]. Total phospholipids from total plasma, erythrocyte
membranes, and LDL- and HDL fractions were transmethylated using boron trifluoride in
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methanol according to Morrison and Smith [30]. Fatty acid methyl esters (FAMEs) were
extracted with hexane and analyzed by gas chromatography on a Hewlett Packard Model
5890 gas chromatograph (Hewlett-Packard, Palo Alto, CA, USA) using a CPSIL-88 column
(100 m × 0.25 mm i.d., film thickness 0.20 µm; Varian, Les Ulis, France) equipped with a
flame ionization detector. Hydrogen was used as the carrier gas (inlet pressure 210 kPa).
The oven temperature was held at 60 ◦C for 5 min, increased to 165 ◦C at 15 ◦C/min and
held for 1 min, and then to 225 ◦C at 2 ◦C/min, and finally held at 225 ◦C for 17 min. The
injector and the detector were maintained at 250 ◦C. FAMEs were identified by comparison
with commercial and synthetic standards. The data were processed using EZChrom Elite
software (Agilent Technologies, Massy, France) and reported as a percentage (mole %) of
the total fatty acids.
2.5. Determination of Total Plasma and Lipoprotein Lutein and Zeaxanthin Concentrations
The concentrations of lutein and zeaxanthin in total plasma and LDL- and HDL-
fractions were determined according to previously described procedures [31,32]. All
further processes were carried out under yellow light. After adding echinenone as an
internal standard, carotenoids were extracted twice with hexane. The extracts were dried
under a stream of nitrogen and then dissolved in a known volume of mobile phase (see
below) for HPLC analysis.
The HPLC system consisted of a solvent degasser (model DG-1580-53, Jasco, Bougue-
nais, France), a pump set up in isocratic mode (model PU-1580 and LG-1580-02, Jasco,
Bouguenais, France), an autosampler (model Spectra System AS300, Thermo Finnigan,
Villebon Sur Yvette, France) maintaining samples at 15 ◦C, a Nucleosil C18 column
(25 mm × 4.6 mm i.d., film thickness 5 µM, Thermo Finnigan, Villebon Sur Yvette, France),
and a VIDAK C18 column (25 mm × 4.6 mm i.d., film thickness 5 µM, GRACE, Altech
France, Epernon, France), both maintained at 37 ◦C by a column heater, a guard column
containing a C18 phase (10 mm × 2 mm i.d., film thickness 5 µM), a light scattering detector
(model MD-1510 Multiwavelength detector, Jasco, Bouguenais, France), and computer data
system (Borwin PDA, Jasco, Bouguenais, France). The mobile phase for the isocratic separa-
tion was 70% acetonitrile, 15% methanol containing 50 mM ammonium acetate, 5% water,
and 10% dichloromethane, and the flow rate was 2 mL/min. Carotenoids were measured
by absorbance at 450 nm and a wavelength scan from 200 to 650 nm. Their concentrations
were determined from peak areas using internal and external standards. Linear calibration
curves were prepared consisting of multiple concentrations of echinenone.
2.6. Measurement of Macular Pigment Optical Density (MPOD)
All participants underwent a comprehensive ocular examination. Their pupils were
dilated with eye drops containing 0.5% tropicamide and 2.5% phenylephrine. MPOD
was measured using a modified confocal scanning laser ophthalmoscope (SLO, model
mpHRA, Heidelberg Engineering, Heidelberg, Germany) by means of autofluorescence
images [33,34]. Each participant was positioned in front of the SLO camera and was
instructed to look straight ahead. After focusing the SLO on the macular area, image
sequences were captured at 488 nm (maximal absorption) and 514 nm (minimal absorption)
at least 30 s after retinal bleaching. MPOD was recorded at eccentricities of 0.5, 1.0, 2.0, and
4.0 degrees, and mean MPOD values were calculated for each using the software provided
by the manufacturer. MPOD was expressed as optical density units (DU).
2.7. Statistical Analyses
Normality of variables was tested by the Shapiro–Wilk test. Log transformations were
performed when the distribution was skewed to obtain normally distributed variables.
Comparison of means was done using the t test. The change between V0 and V4 was
tested using a paired t test. The effect of the supplementation was evaluated by comparing
the mean change in each group using the t test. Sensitivity analysis was performed
with a general linear model adjusted for age, triglycerides, total cholesterol, and LDL
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cholesterol. To have a single test for all eccentricities, we analyzed the four eccentricities
in one mixed model. We used the lmer function of the R package lme4. MPOD was the
dependent variable. The visits (V0, V4) and eccentricity were included in the model with a
random slope and intercept. Spearman correlations were calculated between DHA, lutein,
zeaxanthin, and MPOD. All analyses were performed using R software (available online:
http://www.R-project.org/ accessed on 23 September 2021).
2.8. Sample Size Calculation
The sample size calculation of our trial was based on the MPOD measurement reported
in the study of Vishwanathan et al. (2009) [35]. In this study, there was a nonsignificant
increase in macular pigment at 0.5◦ (0.06 units, SD 0.13) following consumption of 4 eggs
per day for 5 weeks (providing on average 1886 µg of lutein + zeaxanthin per day, n = 37)
(data from the figures). Based on these results, we expected a small increase in the value of
the macular pigment (0.002 units) in the standard group and a more consequent increase in
the value of the macular pigment (0.08 units) for the enriched group. Therefore, estimating
an increase in macular pigment value of ∆ = 0.08 units in the group consuming enriched
eggs, a standard deviation of this increase of σ = 0.13, setting α = 5% (z1−α/2 = 1.96) and
β = 20% (z1−β = 0.8416) and using the formula for determining the minimum number of
participants in a bilateral situation, we obtained the following:
n = 2 ×

(









To compensate for possible protocol deviations and to increase statistical power, we
chose to enroll 50 participants per group.
3. Results
3.1. Baseline Characteristics
The baseline characteristics of the participants are presented in Table 2. For the
two groups, clinical and biological parameters at baseline were in the usual range for
age and sex. There was no difference between the two groups of participants regarding
sex, BMI, blood pressure, heart rate, HDL cholesterol, LDL cholesterol/HDL cholesterol
ratio, MPOD at any degree of eccentricity, or blood carotenoid and DHA concentrations.
However, age, plasma triglycerides, total cholesterol, and LDL cholesterol concentrations
were higher in participants from the enriched group than in those from the standard group.
Because a sensitivity analysis performed with a general linear model adjusted on these four
parameters did not show any effect on the significance of the results, these differences in
age, triglycerides, total cholesterol, and LDL cholesterol concentrations between the groups
of participants at baseline were not taken into account.
Table 2. Baseline characteristics of the participants.






Age, mean (interquartile range), year 29.8 (23–36) 32.8 (24–40)
BMI, mean (SD), kg/m2 21.58 (2.99) 22.13 (2.17)
Blood pressure, mean (SD), mm Hg
Systolic 119.6 (8.90) 121.9 (10.03)
Diastolic 66.97 (7.13) 67.70 (6.81)
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Table 2. Cont.
Baseline Characteristics Standard Group(n = 49)
Enriched Group
(n = 50)
Heart rate, mean (SD), bpm 62.91 (6.44) 63.60 (4.04
Triglycerides, mean (SD), g/L 0.68 (0.30) 0.77 (0.22)
TC, mean (SD), g/L 1.74 (0.27) 1.88 (0.29)
HDL-C, mean (SD), g/L 0.57 (0.11) 0.58 (0.13)
LDL-C, mean (SD), g/L 1.03 (0.25) 1.14 (0.26)
LDL-C/HDL-C, mean (SD) 1.90 (0.66) 2.07 (0.65)
Xanthophyll carotenoids, mean (SD), µg/mL
Lutein 154.4 (62.7) 167.4 (84.3)
Zeaxanthin 17.6 (9.0) 17.7 (10.4)
DHA, mean (SD), mole % of total FA
Plasma 1.94 (0.65) 1.89 (0.53)
Erythrocytes 1.84 (0.94) 2.04 (0.93)
MPOD, mean (SD)
0.5◦ 0.551 (0.20) 0.562 (0.15)
1◦ 0.459 (0.15) 0.474 (0.13)
2◦ 0.255 (0.09) 0.260 (0.08)
4◦ 0.113 (0.045) 0.113 (0.040)
Abbreviations: SD = standard deviation, V0 = Visit 0, V4 = Visit 4, BMI = body mass index, bpm = beat per minute,
TC = total cholesterol, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol,
FA = fatty acid, DHA = docosahexaenoic acid, EPA = eicosapentaenoic acid, MPOD = macular pigment optical
density.
Data from food intake questionnaires at baseline did not show any statistically signif-
icant difference in total energy, protein, carbohydrate, total fat, saturated fatty acid, mo-
nounsaturated fatty acid, polyunsaturated fatty acid, DHA, cholesterol, fiber, carotenoid,
vitamin (A, E, D), or micronutrient (such as sodium, calcium, magnesium, potassium, iron,
and selenium) intake between the two groups of participants (Table S1).
3.2. Adverse Events and Compliance
No adverse events related to the study were observed or reported by participants.
During the four-month intervention, the participants consumed an average of 13.5 eggs
(mean ± 0.7(SD)) per week instead of 14 (13.50 ± 0.65 in control group, 13.55 ± 0.72 in
enriched group), corresponding to an adherence rate of 93.6%.
3.3. Effect of Lutein- and DHA-Enriched Egg Consumption on Clinical Parameters
Even if the change was low (+1.3%), BMI was increased 4 months after egg consump-
tion in the enriched group only. Except for this parameter, no difference in the mean change
in clinical parameters between V0 and V4 was observed in the standard vs. enriched
groups. We also focused the description of the results on the total sample (Table 3).
No effect was observed on heart rate or triglyceride plasma concentration after
4 months of egg consumption. However, total cholesterol (1.81 g/L at V0 vs. 1.90 g/L
at V4, p = 6.00 × 10−5), HDL cholesterol (0.57 g/L at V0 vs. 0.59 g/L at V4, p = 0.013),
and LDL cholesterol (1.09 g/L at V0 vs. 1.15 g/L at V4, p = 0.0002) significantly increased
for all participants after 4 months of daily consumption of two eggs per day. The LDL
cholesterol/HDL cholesterol ratio also tended to increase (p = 0.054). Blood pressure de-
creased for all participants consuming two eggs per day for 4 months (120.7 mmHg at V0
vs. 118.4 mmHg at V4).
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and V4 in Enriched
Group vs. Standard
Group
V0 V4 p-Value (1) V0 V4 p-Value (1) V0 V4 p-Value (1) p-Value (2)
BMI, mean (SD), kg/m2 21.85 (2.61) 21.97 (2.63) 0.14 21.58 (2.99) 21.52 (2.92) 0.66 22.13 (2.17) 22.42 (2.25) 0.004 0.031
Blood Pressure, mean (SD), mm Hg
Systolic 120.7 (9.51) 118.4 (8.71) 0.005 119.6 (8.90) 116.6 (8.74) 0.023 121.9 (10.03) 120.1 (8.41) 0.08 0.55
Diastolic 67.34 (6.94) 63.95 (6.67) 2.40 × 10−5 66.97 (7.13) 63.18 (6.67) 0.003 67.70 (6.81) 64.72 (6.65) 0.001 0.59
Heart Rate, mean (SD), bpm 63.26 (5.36) 62.84 (4.25) 0.34 62.91 (6.44) 62.47 (4.51) 0.37 63.60 (4.04 63.20 (3.99) 0.77 0.36
Triglycerides, mean (SD), g/L 0.72 (0.26) 0.74 (0.34) 0.92 0.68 (0.30) 0.68 (0.27) 0.73 0.77 (0.22) 0.80 (0.39) 0.84 0.70
TC, mean (SD), g/L 1.81 (0.29) 1.90 (0.31) 6.00 × 10−5 1.74 (0.27) 1.80 (0.25) 0.043 1.88 (0.29) 2.00 (0.33) 0.0004 0.14
HDL-C, mean (SD), g/L 0.57 (0.12) 0.59 (0.12) 0.013 0.57 (0.11) 0.58 (0.10) 0.17 0.58 (0.13) 0.60 (0.14) 0.03 0.61
LDL-C, mean (SD), g/L 1.09 (0.26) 1.15 (0.27) 0.0002 1.03 (0.25) 1.08 (0.21) 0.053 1.14 (0.26) 1.23 (0.29) 0.001 0.17
LDL-C/HDL-C, mean (SD) 1.99 (0.66) 2.03 (0.63) 0.054 1.90 (0.66) 1.89 (0.50) 0.42 2.07 (0.65) 2.16 (0.71) 0.049 0.47
Abbreviations: SD = standard deviation, V0 = Visit 0, V4 = Visit 4, BMI = body mass index, bpm = beat per minute, TC = total cholesterol, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density
lipoprotein cholesterol. (1) The change between V0 and V4 was tested using a paired t test. (2) The effect of the supplementation was evaluated by comparing the mean change in each group using the t test.
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3.4. Effect of Eggs Consumption on MPOD
Compared with baseline, MPOD increased slightly but significantly at all eccentricities
in the total sample after 4 months of egg consumption (p = 0.03 at 0.5◦; p = 0.00008 at 1◦;
p = 0.0005 at 2◦; and p = 0.0028 at 4◦; Table 4). Similar results were observed in participants
consuming standard eggs, except at 0.5◦ eccentricity. In participants consuming enriched
eggs, a significant increase in MPOD at 1◦ of eccentricity was only observed after 4 months
of egg consumption (p = 0.025). However, a comparison of the mean change in MPOD at
all eccentricities between V0 and V4 in the enriched group vs. the standard group did not
show any difference (+2%, p = 0.98 at 0.5◦; +3%, p = 0.8 at 1◦; +1%, p = 0.4 at 2◦; and −3%,
0.19 at 4◦). In the mixed model including all eccentricities, MPOD significantly increased
between V0 and V4 in the whole sample (p < 0.002) and in the standard group (p < 0.004)
and tended to be significant in the enriched group (p = 0.06). The impact of the group on
the MPOD change was not significant (p = 0.68).
3.5. Effect of Lutein- and DHA-Enriched Egg Consumption on Plasma and Lipoprotein Content in
Lutein and Zeaxanthin
The consumption of two eggs per day for 4 months induced a significant increase in
total plasma lutein concentrations in participants from the standard group (from 154 ng/mL
to 178 ng/mL (+15%), p = 0.001) and the enriched group (from 167 ng/mL to 369 ng/mL
(+120%), p = 3.13 × 10−16; Table 4). The mean changes in total plasma lutein concentrations
between V0 and V4 were significantly greater in participants consuming the enriched eggs
than in participants consuming the standard eggs (p = 5.26 × 10−13). Similar results were
observed for plasmatic zeaxanthin concentrations, as they increased from 17.6 ng/mL
to 22.7 ng/mL (+29%) in the standard group (p = 7.13 × 10−6) and from 17.7 ng/mL
to 29.2 ng/mL (+65%) in the enriched group (p = 3.38 × 10−13). For lutein, the mean
changes in total plasma zeaxanthin concentrations between V0 and V4 were also greater in
participants consuming eggs enriched with xanthophylls (p = 0.003).
The increase in the concentrations of lutein and zeaxanthin in total plasma of all
participants was likely to be the consequence of the enrichment of HDL lipoproteins in
these carotenoids (from 87.4 ng/mL to 99.3 ng/mL for lutein in standard group, p = 0.02;
from 91.4 ng/mL to 179.3 ng/mL for lutein in enriched group, p = 4.31 × 10−11; from
10.4 ng/mL to 13.3 ng/mL for zeaxanthin in standard group, p = 0.0005; from 10.0 ng/mL
to 15.0 ng/mL for lutein in enriched group, p = 1.0 × 10−9; Table 4). In participants
consuming the enriched eggs, the enrichment of HDL in lutein and zeaxanthin was even
larger than in the standard group (p = 1.30 × 10−8 for lutein and p = 0.01 for zeaxanthin
when comparing the change of both groups). In the enriched group, a significant increase
in lutein and zeaxanthin concentrations in LDL lipoproteins was also observed after four
months of study (from 85.6 ng/mL at V0 to 182.5 ng/mL at V4 for lutein, p = 1.75 × 10−12;
from 9.5 ng/mL at V0 to 14.4 ng/mL at V4 for zeaxanthin, p = 1.50 × 10−6). However, this
increase was not observed for the standard group.
By checking for associations between MPOD and xanthophyll plasma concentrations
at the end of the study, we identified a strong correlation in participants consuming enriched
eggs between HDL concentrations of lutein and MPOD at 0.5◦ and 1◦ of eccentricities,
where this carotenoid is most concentrated in the human retina [36,37] (rho = 0.385, p = 0.008
and rho = 0.461, p = 0.001, respectively; Figure 2). Similar results were observed at 2◦
and 4◦ eccentricities (rho = 0.479, p = 0.001 and rho = 0.474, p = 0.001, respectively; data
not shown). However, no significant association was observed between MPOD and HDL
concentrations of lutein in the standard group. In participants consuming standard eggs,
statistically significant associations were observed between LDL concentrations of lutein
and MPOD at 2◦ and 4◦ of eccentricities (rho = 0.329, p = 0.029 and rho = 0.338, p = 0.025,
respectively; data not shown). No relevant association was observed between MPOD and
total plasma, HDL, and LDL zeaxanthin concentrations.
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and V4 in Enriched
Group vs. Standard
Group
V0 V4 p-Value (1) V0 V4 p-Value (1) V0 V4 p-Value (1) p-Value (2)
MPOD, mean (SD), density units
0.5◦ 0.557 (0.18) 0.564 (0.18) 0.03 0.551 (0.20) 0.558 (0.20) 0.11 0.562 (0.15) 0.569 (0.16) 0.14 0.98
1◦ 0.466 (0.14) 0.475 (0.14) 0.0008 0.459 (0.15) 0.467 (0.15) 0.01 0.474 (0.13) 0.483 (0.13) 0.025 0.8
2◦ 0.258 (0.08) 0.265 (0.08) 0.0005 0.255 (0.09) 0.264 (0.09) 0.0008 0.260 (0.08) 0.266 (0.08) 0.079 0.4
4◦ 0.113 (0.04) 0.117 (0.04) 0.0028 0.113 (0.045) 0.119 (0.04) 0.0013 0.113 (0.040) 0.115 (0.04) 0.22 0.19
Lutein, mean (SD)
Total plasma, ng/mL 160.9 (74.2) 273.7 (177.1) 1.17 × 10−14 154.4 (62.7) 178.1 (76.78) 0.001 167.4 (84.3) 369.3 (197.1) 3.13 × 10−16 5.26 × 10−13
HDL fraction, ng/mg proteins 89.44 (46.27) 139.73 (87.07) 1.15 × 10−10 87.41 (37.86) 99.31 (47.35) 0.02 91.44 (53.60) 179.26 (98.69) 4.37 × 10−11 1.30 × 10−8
LDL fraction. ng/mg proteins 84.71 (44.60) 131.84 (90.81) 5.60 × 10−8 83.88 (41.18) 82.28 (37.66) 0.90 85.56 (48.31) 182.5 (101.1) 1.75 × 10−12 5.36 × 10−11
Zeaxanthin, mean (SD)
Total plasma, ng/mL 17.6 (9.7) 26.0 (14.0) 1.31 × 10−15 17.6 (9.0) 22.7 (10.76) 7.13 × 10−6 17.7 (10.4) 29.2 (16.1) 3.38 × 10−13 0.003
HDL fraction, ng/mg proteins 10.20 (6.34) 14.17 (8.56) 1.01 × 10−11 10.43 (5.87) 13.32 (8.17) 5.30 × 10−4 9.97 (6.83) 15.0 (8.95) 1.00 × 10−9 0.01
LDL fraction, ng/mg proteins 9.64 (6.80) 12.47 (8.43) 1.31 × 10−6 9.74 (6.60) 10.5 (6.42) 0.05 9.53 (7.07) 14.4 (9.76) 1.50 × 10−6 0.01
DHA, mean (SD), mole % of total FA
Total plasma 1.91 (0.59) 2.32 (0.71) 1.54 × 10−10 1.94 (0.65) 2.07 (0.65) 0.03 1.89 (0.53) 2.56 (0.68) 1.00 × 10−11 2.15 × 10−6
Red Blood cells 1.94 (0.93) 3.54 (1.41) 7.80 × 10−20 1.84 (0.94) 2.97 (1.34) 3.11 × 10−7 2.04 (0.93) 4.10 (1.24) 2.71 × 10−15 5.15 × 10−3
HDL fraction 2.48 (0.70) 2.90 (0.84) 1.36 × 10−8 2.48 (0.72) 2.62 (0.75) 0.090 2.47 (0.69) 3.18 (0.84) 2.62 × 10−9 1.26 × 10−5
LDL fraction 1.57 (0.53) 1.81 (0.58) 3.53 × 10−5 1.59 (0.50) 1.63 (0.53) 0.505 1.56 (0.49) 1.99 (0.59) 1.49 × 10−5 2.70 × 10−5
Abbreviations: SD = standard deviation. V0 = Visit 0, V4 = Visit 4, FA = fatty acid, DHA = docosahexaenoic acid, MPOD = macular pigment optical density. In HDL, values are expressed as the mean ± SD in ng
per mg of ApoA1. In LDL, values are expressed as the mean ± SD in ng per mg of ApoB10. Comparison of means was done using the t test. (1) The change between V0 and V4 was tested using a paired t test.
(2) The effect of the supplementation was evaluated by comparing the mean change in each group using the t test.
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Lutein concentrations are expressed as ng/mL of plasma in total plasma and as ng/mg of proteins in HDL and LDL frac-
tions (y axis). MPOD is expressed as density units (x axis). n = 48 in standard group, n = 49 in enriched group. Correlations 
were assessed by using Spearman’s test. 
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Figure 2. Correlation between total plasma, HDL, and LDL concentrations of lutein and MPOD at 0.5◦ and 1◦ eccentricities.
Lutein concentrations are expressed as ng/mL of plasma in total plasma and as ng/mg of proteins in HDL and LDL fractions
(y axis). MPOD is expressed as density units (x axis). n = 48 in standard group, n = 49 in enriched group. Correlations were
assessed by using Spearman’s test.
3.6. Effect of Lutein- and DHA-Enriched Egg Consumption on Total Plasma, Red Blood Cells,
and Lipoprotein Concentrations of DHA
The concentrations of DHA significantly increased in the total plasma and in the red
blood cells of participants from both groups (Table 4). For plasma lutein, the increase
in DHA concentrations was more substantial in participants consuming enriched eggs
(plasma: from 1.94% to 2.07% of total fatty acids in standard group, p = 0.03; from 1.89% to
2.56% of total fatty acids in the enriched group, p = 1.00 × 10−11; red blood cells: from 1.84%
to 2.97% of total fatty acids in standard group, p = 3.1 × 10−7; from 2.04% to 4.10% of total
fatty acids in the enriched group, p = 2.71 × 10−15). The large increase in plasma and red
blood cell DHA concentrations in participants from the enriched group was associated
with a strong elevation of DHA concentrations in HDL and LDL frac ions (from 2.47% to
3.18% of total fatty acids in HDL, p = 2.62 × 10−9; fr m 1.56% to 1.99% of total fatty acids
in LDL, p = 1.49 × 10−5). No variation in DHA concentrations was observed in HDL and
LDL fractions of participants consuming standard eggs.
4. Discussion
The obj ctive of this study w s to determine whether he daily consumption of two
eggs enriched with lutein and zeax nthin (from alfalf protein concentrate) and DHA (from
Schizochytrium sp. microalgae) would affect macular pigment optical density and blood
concentrations of xanthophylls and fatty acids in healthy human participants.
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In this trial, we decided to use low amounts of xanthophylls and DHA and to deliver
them through a dietary vector that may have given them excellent bioavailability. Indeed,
it is known that the bioavailability of lipophilic nutrients such as lutein, zeaxanthin, and
fatty acids depends on the matrix in which they are incorporated [25,38]. Several studies
have shown that serum concentrations of xanthophylls and MPOD increase more when
present in a lipid matrix such as egg yolk when compared with other food products or
pure preparations as dietary supplements (reviewed by Thurnham, 2007 [39]). Egg yolk
is also known to be rich in lipids and to contain approximately one-third of these lipids
in the phospholipid form, whereas triglycerides represent the major lipid class in food
products and food supplements. It is now well accepted that PUFAs provided by dietary
phospholipids have a higher intestinal bioavailability than those delivered by triglycerides
(reviewed by Schuchardt and Hahn, 2013 [25]).
As a consequence, whereas the majority of studies using food supplements have used
daily doses of 6 mg of lutein and 2 mg of zeaxanthin, we gave only 1.90 mg and 0.20 mg of
these xanthophylls per day, respectively, and only 269 mg of DHA per day, which is much
lower than previous intervention trials in ophthalmology [40,41]. Because the standard
eggs naturally contained lutein, zeaxanthin, and DHA (daily doses of 0.24 mg, 0.13 mg,
and 75 mg, respectively), the concentrations of these molecules were significantly increased
in the total plasma and HDL fraction for lutein and zeaxanthin and in the total plasma for
DHA in participants from the standard group. In participants consuming the enriched
eggs, the increase in lutein, zeaxanthin, and DHA was even greater. These results are in
accordance with the Blesso and collaborators’ study showing a significant enrichment of
isolated HDL and LDL fractions in lutein and zeaxanthin in participants consuming three
whole eggs per day [42]. It is well known that lutein and zeaxanthin are mostly associated
with HDL, followed by LDL and VLDL [43]. In our study, plasma lutein incorporation
was 2.2-fold higher after 4 months of enriched egg consumption compared with base-
line. Comparable results were observed by Kelly and collaborators since a 2.3-fold higher
concentration was observed in serum lutein after daily enriched egg consumption (ratio
lutein/mesozeaxanthin 1:1) for 2 months [44]. This increase was higher than for lutein sup-
plement; Obana and collaborators showed that 10 mg of lutein supplement from marigold
oleoresin increased lutein plasma concentration by 1.7 times compared with baseline after
6 months of supplementation in 36 participants [45]. Similarly, Bone and collaborators
observed approximately 2-fold higher carotenoid serum concentration with Lumega-Z (a
lipid-based micronized liquid medical food) containing 28 mg of lutein, zeaxanthin, and
meso-zeaxanthin after 12 weeks of supplementation in healthy participants [46]. It can then
be hypothesized from these data that lutein from eggs was more incorporated in plasma
than lutein from the supplement. Chung and collaborators demonstrated that the lutein
bioavailability from egg is higher than that from other sources such as spinach [47]. This
could be explained by the presence of phospholipids in eggs. Indeed, it was shown that a
supplement of lutein plus phospholipids was more efficient in increasing plasma lutein
concentration than a conventional lutein supplement [48]. Therefore, egg consumption
enhanced carotenoid absorption from other carotenoid-rich foods, such as a raw mixed
vegetable salad [49]. The food matrix is thus greatly important for carotenoid absorption.
Moreover, even if natural sources could not contain as many lutein and/or zeaxanthin
levels (ex 10 mg) as food supplements, it does not alter their efficiency due to their high
absorption potential. It might also be interesting to explore in future studies other natural
sources of carotenoids than eggs.
Considering MPOD, we observed a slight but significant increase in MPOD at all
eccentricities for all participants consuming two eggs per day for 4 months (total sample,
Table 4, V4 vs. V0). However, there was no further increase in the MPOD value in the
enriched group compared with the standard group. This could be explained by the standard
egg composition. Standard eggs contained a meaningful amount of lutein/zeaxanthin
(~24% of the daily intake observed in the French population [50]) and DHA (~15% of the
daily intake observed in the French population [51]) content; thus, due to the presence of
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phospholipids in eggs, these contents could be sufficient to increase the macular pigment
during the four-month period of the study. On the other hand, participants with lower
MPOD levels at baseline responded well to lutein supplementation [45]. As the participants
of our study were healthy, it was not surprising to observe only a slight increase in MPOD.
It is interesting to emphasize that similar data were recently reported by other teams using
dietary supplements [52] or eggs [44]. After 6 months of lutein and zeaxanthin dietary
supplementation and despite plasma levels showing continuous exposure to lutein and
zeaxanthin, MPOD was not modified [52]. In the same way, the consumption of one egg
per day enriched with lutein and zeaxanthin for 8 weeks did not affect macular pigment
levels, although an increase in serum lutein and zeaxanthin was observed [44]. These
results could be explained by a high MPOD level at baseline, limiting the ability to increase
further with supplementation. However, based on secondary exploratory analyses of the
AREDS2 study, it is actually well accepted that the use of lutein/zeaxanthin supplements
is beneficial in reducing the risk of AMD progression [53]. A study of patients over a
15-year period also showed that a moderate consumption of eggs can significantly reduce
a patient’s risk of developing incident, late-stage age-related macular degeneration [54].
The main originality of our study was the correlation observed between MPOD at all
eccentricities (0.5◦, 1◦, 2◦, and 4◦) and lutein concentration in HDL. To our knowledge, this
is the first report of this correlation. Some studies have reported an association between
MPOD and serum lutein and/or zeaxanthin levels [55–57]. However, as in our study, this
correlation was not observed in all findings [58,59]. Due to the importance of HDL in lutein
transport [18], lutein concentration in HDL may thus be a novel biological marker and
correlate of MPOD after lutein supplementation.
In this study, whereas plasma triglycerides were unchanged, the levels of total choles-
terol, HDL cholesterol, and LDL cholesterol were slightly but significantly increased in
the whole sample, thus suggesting that a daily consumption of two eggs for four months
would affect cholesterol metabolism. Interestingly, the LDL/HDL ratio was not signifi-
cantly increased. For a few decades, common beliefs have emerged on the relationship
between egg consumption and health. Attention was first drawn to the cholesterol content
of eggs through studies suggesting that cholesterol-rich food consumption may elevate
blood cholesterol and increase the risk of coronary heart disease [60]. However, recent trials
have revealed that the regular consumption of eggs is not associated with an increased
risk of coronary heart disease [55,61–64], although heavy egg consumption over a longer
period of time requires studies to point out possible adverse effects. Considering our study
results, daily egg consumption may be something to consider.
In the current trial, a decrease in blood pressure was observed for all participants
consuming two eggs per day for 4 months. This decrease could be due to the protein
content of eggs. Indeed, Teunissen-Beekman and collaborators showed in 2012 that blood
pressure can be lowered by exchanging the intake of carbohydrates with an increased
intake of proteins in the context of an isocaloric weight-maintaining diet [65]. Additionally,
a change in plasma fatty acid and lipoprotein profile towards the anti-atherogenic range
observed in the group consuming DHA-enriched eggs (i.e., higher plasma DHA, HDLC,
without any change in plasma triglycerides and balanced LDL/HDL ratio) could contribute
to improved endothelial reactivity and lower diastolic blood pressure, which is consistent
with observations from large randomized cardiovascular prevention studies [66].
One of the limitations of the current study is the methodology used to evaluate MPOD.
Despite the great increase in serum lutein/zeaxanthin in participants consuming enriched
eggs for 4 months, the increase in MPOD was limited. A recent meta-analysis revealed that
lutein, zeaxanthin, and meso-zeaxanthin supplementation improved MPOD in both AMD
patients and healthy participants in a dose-dependent manner [67]. However, although we
observed an increase in MPOD in the enriched group, we expected higher MPOD values
than those observed in the standard group by using a modified confocal scanning laser
ophthalmoscope (SLO, model mpHRA, Heidelberg Engineering, Heidelberg, Germany), a
highly reproductible method [68]. Thus, regarding the experimental results, we could con-
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sider that the methodology used to evaluate MPOD values in this study was not optimal.
The most suitable method for measuring macular pigment was not clearly identified [69].
Scientific debate is still open; numerous studies have compared different methods and
investigated the advantages and limitations of measurement techniques [70–72]. Another
limitation of our study could be the age of the sample. We speculate that young people may
not be a useful group for evaluating the effect of dietary supplementation on preserving
macular health. An older sample might have responded differently to dietary supplemen-
tation. Moreover, as macular pigment is relatively stable over a long period, greater study
duration could have allowed the observation of a higher MPOD increase. Nevertheless,
the study protocol was well designed (double-blind, randomized), and compliance with
eggs was good (>93% overall). Furthermore, no subject was lost during the trial period
(4 months).
5. Conclusions
This study showed that the consumption of two eggs (standard or lutein/DHA-
enriched) per day for 4 months slightly but significantly increased MPOD at all eccen-
tricities. Plasma lutein, zeaxanthin, and DHA concentrations increased in both groups
but to a greater extent in the enriched egg group. The major original result of this trial
is the correlation between the MPOD value and HDL lutein concentration observed in
participants consuming enriched eggs. However, this correlation should be confirmed by
other clinical studies.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/nu13103347/s1, Table S1: Baseline food intake of the participants.
Author Contributions: C.S.-B., N.A., E.S., C.T., A.B., A.M., L.B., C.D., P.B. and J.-M.L. designed the
research (scientific committee); C.S.-B., S.D. and M.C. conducted the research; A.T. and B.S. provided
access to an ultracentrifuge; L.D. performed the statistical analysis; C.S.-B., N.A., E.S., C.T., A.B., A.M.,
L.B., C.D., P.B. and J.-M.L. analyzed the data (scientific committee); and C.S.-B., N.A. and J.-M.L.
wrote the paper. All authors have read and agreed to the published version of the manuscript.
Funding: This work was supported by OSEO/BPI France (public funder). The funders had no role
in the design, implementation, analysis, or interpretation of the data. Mixscience provided the eggs
during the study. Roquette was in charge of egg composition analysis and egg safety control.
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki, and the study was approved by the Ethics Committee of Nord Ouest IV
(CHU Lille, Lille, France, study number: 2011-A00364-37 accepted on 3 May 2011).
Informed Consent Statement: Informed consent was obtained from all participants involved in the
study. Written informed consent to publish this paper was obtained from the patients.
Data Availability Statement: The data presented in this study are available on request from the
corresponding author.
Acknowledgments: The authors would like to thank Stéphane Grégoire and Lucy Martine from
the Eye and Nutrition Research Group, INRA, Dijon, France, for fatty acid and lutein/zeaxanthin
analyses and Emmanuelle Vallez from Institut Pasteur de Lille, U1011-EGID, for apolipoprotein
assays.
Conflicts of Interest: C.T. works for ROQUETTE. A.M. and A.B. are employed by MIXSCIENCE.
C.D. is a consultant for Allergan, Bausch + Lomb, Laboratoires Théa, Novartis, and Roche. The other
authors declare no conflict of interest.
References
1. Lim, L.S.; Mitchell, P.; Seddon, J.M.; Holz, F.G.; Wong, T.Y. Age-related macular degeneration. Lancet 2012, 379, 1728–1738.
[CrossRef]
2. Tan, J.S.L.; Wang, J.J.; Flood, V.; Rochtchina, E.; Smith, W.; Mitchell, P. Dietary antioxidants and the long-term incidence of
age-related macular degeneration. Ophthalmology 2008, 115, 334–341. [CrossRef] [PubMed]
Nutrients 2021, 13, 3347 15 of 17
3. Delcourt, C.; Carrière, I.; Delage, M.; Barberger-Gateau, P.; Schalch, W. Plasma lutein and zeaxanthin and other carotenoids
as modifiable risk factors for age-related maculopathy and cataract: The POLA study. Investig. Opthalmol. Vis. Sci. 2006, 47,
2329–2335. [CrossRef] [PubMed]
4. Delcourt, C.; The POLANUT Study Group; Carrière, I.; Cristol, J.-P.; Lacroux, A.; Gerber, M. Dietary fat and the risk of age-related
maculopathy: The POLANUT study. Eur. J. Clin. Nutr. 2007, 61, 1341–1344. [CrossRef] [PubMed]
5. Moeller, S.M.; Parekh, N.; Tinker, L.; Ritenbaugh, C.; Blodi, B.; Wallace, R.B.; Mares, J.A. Associations between intermediate
age-related macular degeneration and lutein and zeaxanthin in the carotenoids in age-related eye disease study (CAREDS):
Ancillary study of the women’s health Initiative. Arch. Ophthalmol. 2006, 124, 1151–1162. [CrossRef] [PubMed]
6. Augood, C.; Chakravarthy, U.; Young, I.; Vioque, J.; de Jong, P.T.V.M.; Bentham, G.; Rahu, M.; Seland, J.; Soubrane, G.;
Tomazzoli, L.; et al. Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations
with neovascular age-related macular degeneration. Am. J. Clin. Nutr. 2008, 88, 398–406. [CrossRef]
7. SanGiovanni, J.P.; Agrón, E.; Meleth, A.D.; Reed, G.F.; Sperduto, R.D.; Clemons, T.; Chew, E.Y.; Age-Related Eye Disease Study
Research Group. Omega-3 long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular
degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the age-related eye disease
study. Am. J. Clin. Nutr. 2009, 90, 1601–1607. [CrossRef] [PubMed]
8. Whitehead, A.J.; Mares, J.A.; Danis, R.P. Macular pigment: A review of current knowledge. Arch. Ophthalmol. 2006, 124, 1038–1045.
[CrossRef]
9. Barker, F.M.; Snodderly, D.; Johnson, E.J.; Schalch, W.; Koepcke, W.; Gerss, J.; Neuringer, M. Nutritional manipulation of primate
retinas, V: Effects of Lutein, Zeaxanthin, and n-3 fatty acids on retinal sensitivity to blue-light-induced damage. Investig. Opthalmol.
Vis. Sci. 2011, 52, 3934–3942. [CrossRef]
10. Junghans, A.; Sies, H.; Stahl, W. Macular pigments lutein and zeaxanthin as blue light filters studied in liposomes. Arch. Biochem.
Biophys. 2001, 391, 160–164. [CrossRef]
11. Davies, N.; Morland, A.B. Macular pigments: Their characteristics and putative role. Prog. Retin. Eye Res. 2004, 23, 533–559.
[CrossRef]
12. Fliesler, S.J.; Anderson, R.E. Chemistry and metabolism of lipids in the vertebrate retina. Prog. Lipid Res. 1983, 22, 79–131.
[CrossRef]
13. Litman, B.J.; Mitchell, D.C. A role for phospholipid polyunsaturation in modulating membrane protein function. Lipids 1996, 31,
S193–S197. [CrossRef] [PubMed]
14. Bazan, N.G. Homeostatic regulation of photoreceptor cell integrity: Significance of the potent mediator neuroprotectin D1
biosynthesized from docosahexaenoic acid the proctor lecture. Investig. Opthalmol. Vis. Sci. 2007, 48, 4866–4881. [CrossRef]
[PubMed]
15. Bourre, J.M.; Francois, M.; Youyou, A.; Dumont, O.; Piciotti, M.; Pascal, G.; Durand, G. The effects of dietary alpha-linolenic acid
on the composition of nerve membranes, enzymatic activity, amplitude of electrophysiological parameters, resistance to poisons
and performance of learning tasks in rats. J. Nutr. 1989, 119, 1880–1892. [CrossRef] [PubMed]
16. Weisinger, H.S.; Vingrys, A.J.; Sinclair, A.J. The effect of docosahexaenoic acid on the electroretinogram of the guinea pig. Lipids
1996, 31, 65–70. [CrossRef]
17. Organisciak, D.T.; Darrow, R.M.; Jiang, Y.L.; Blanks, J.C. Retinal light damage in rats with altered levels of rod outer segment
docosahexaenoate. Investig. Ophthalmol. Vis. Sci. 1996, 37, 2243–2257.
18. Wang, W.; Connor, S.L.; Johnson, E.J.; Klein, M.L.; Hughes, S.; Connor, W.E. Effect of dietary lutein and zeaxanthin on plasma
carotenoids and their transport in lipoproteins in age-related macular degeneration. Am. J. Clin. Nutr. 2007, 85, 762–769.
[CrossRef]
19. Kijlstra, A.; Tian, Y.; Kelly, E.R.; Berendschot, T.T. Lutein: More than just a filter for blue light. Prog. Retin. Eye Res. 2012, 31,
303–315. [CrossRef]
20. Roche, H.M.; Gibney, M.J. Effect of long-chain n-3 polyunsaturated fatty acids on fasting and postprandial triacylglycerol
metabolism. Am. J. Clin. Nutr. 2000, 71, 232s–237s. [CrossRef] [PubMed]
21. Holub, B.J. Docosahexaenoic acid (DHA) and cardiovascular disease risk factors. Prostaglandins Leukot. Essent. Fat. Acids 2009, 81,
199–204. [CrossRef]
22. Johnson, E.J.; Chung, H.-Y.; Caldarella, S.M.; Snodderly, D.M. The influence of supplemental lutein and docosahexaenoic acid on
serum, lipoproteins, and macular pigmentation. Am. J. Clin. Nutr. 2008, 87, 1521–1529. [CrossRef] [PubMed]
23. García-Layana, A.; Recalde, S.; Alamán, A.S.; Robredo, P.F. Effects of lutein and docosahexaenoic acid supplementation on
macular pigment optical density in a randomized controlled trial. Nutrients 2013, 5, 543–551. [CrossRef]
24. Dawczynski, J.; Jentsch, S.; Schweitzer, D.; Hammer, M.; Lang, G.E.; Strobel, J. Long term effects of lutein, zeaxanthin and
omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: The LUTEGA study. Graefe’s Arch.
Clin. Exp. Ophthalmol. 2013, 251, 2711–2723. [CrossRef]
25. Schuchardt, J.P.; Hahn, A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot. Essent. Fat. Acids 2013, 89, 1–8.
[CrossRef] [PubMed]
26. Pieroni, G.; Coste, T.C. Egg fatty acids composition. Nutritional interest and health value. Cah. Nutr. Diététique 2010, 45, 261–266.
[CrossRef]
Nutrients 2021, 13, 3347 16 of 17
27. Bourre, J.-M. L’œuf naturel multi-enrichi: Des apports élevés en nutriments, notamment acides gras oméga-3, en vitamines,
minéraux et caroténoïdes. Med. Nutr. 2005, 41, 116–134. [CrossRef]
28. Havel, R.J.; Eder, H.A.; Bragdon, J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in
human serum. J. Clin. Investig. 1955, 34, 1345–1353. [CrossRef]
29. Moilanen, T.; Nikkari, T. The effect of storage on the fatty acid composition of human serum. Clin. Chim. Acta 1981, 114, 111–116.
[CrossRef]
30. Morrison, W.R.; Smith, L.M. Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride—
Methanol. J. Lipid Res. 1964, 5, 600–608. [CrossRef]
31. Lyan, B.; Azaïs-Braesco, V.; Cardinault, N.; Tyssandier, V.; Borel, P.; Alexandre-Gouabau, M.C.; Grolier, P. Simple method for
clinical determination of 13 carotenoids in human plasma using an isocratic high-performance liquid chromatographic method. J.
Chromatogr. B Biomed. Sci. Appl. 2001, 751, 297–303. [CrossRef]
32. Toomey, M.B.; McGraw, K.J. Modified saponification and HPLC methods for analyzing carotenoids from the retina of quail:
Implications for its use as a nonprimate model species. Investig. Opthalmol. Vis. Sci. 2007, 48, 3976–3982. [CrossRef]
33. Wüstemeyer, H.; Moessner, A.; Jahn, C.; Wolf, S. Macular pigment density in healthy subjects quantified with a modified confocal
scanning laser ophthalmoscope. Graefe’s Arch. Clin. Exp. Ophthalmol. 2003, 241, 647–651. [CrossRef]
34. Wüstemeyer, H.; Jahn, C.; Nestler, A.; Barth, T.; Wolf, S. A new instrument for the quantification of macular pigment density:
First results in patients with AMD and healthy subjects. Graefe’s Arch. Clin. Exp. Ophthalmol. 2002, 240, 666–671. [CrossRef]
35. Vishwanathan, R.; Goodrow-Kotyla, E.F.; Wooten, B.R.; Wilson, T.A.; Nicolosi, R.J. Consumption of 2 and 4 egg yolks/d for 5 wk
increases macular pigment concentrations in older adults with low macular pigment taking cholesterol-lowering statins. Am. J.
Clin. Nutr. 2009, 90, 1272–1279. [CrossRef]
36. Hammond, B.R.; Wooten, B.R.; Snodderly, D.M. Individual variations in the spatial profile of human macular pigment. J. Opt. Soc.
Am. A 1997, 14, 1187–1196. [CrossRef] [PubMed]
37. Berendschot, T.T.J.M.; van Norren, D. Macular pigment shows ringlike structures. Investig. Opthalmol. Vis. Sci. 2006, 47, 709–714.
[CrossRef] [PubMed]
38. Evans, M.; Beck, M.; Elliott, J.; Etheve, S.; Roberts, R.; Schalch, W. Effects of formulation on the bioavailability of lutein and
zeaxanthin: A randomized, double-blind, cross-over, comparative, single-dose study in healthy subjects. Eur. J. Nutr. 2013, 52,
1381–1391. [CrossRef] [PubMed]
39. Thurnham, D.I. Macular zeaxanthins and lutein—A review of dietary sources and bioavailability and some relationships with
macular pigment optical density and age-related macular disease. Nutr. Res. Rev. 2007, 20, 163–179. [CrossRef]
40. Souied, E.H.; Delcourt, C.; Querques, G.; Bassols, A.; Merle, B.M.; Zourdani, A.; Smith, T.; Benlian, P.; Nutritional AMD Treatment
2 Study Group. Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: The nutritional
AMDtreatment 2 study. Ophthalmology 2013, 120, 1619–1631. [CrossRef]
41. Age-Related Eye Disease Study 2 Research Group. Lutein + Zeaxanthin and Omega-3 fatty acids for age-related macular
degeneration. JAMA 2013, 309, 2005–2015. [CrossRef] [PubMed]
42. Blesso, C.N.; Andersen, C.J.; Bolling, B.W.; Fernandez, M.L. Egg intake improves carotenoid status by increasing plasma HDL
cholesterol in adults with metabolic syndrome. Food Funct. 2013, 4, 213–221. [CrossRef] [PubMed]
43. Thomas, S.E.; Harrison, E.H. Mechanisms of selective delivery of xanthophylls to retinal pigment epithelial cells by human
lipoproteins. J. Lipid Res. 2016, 57, 1865–1878. [CrossRef] [PubMed]
44. Kelly, D.; Nolan, J.M.; Howard, A.N.; Stack, J.; Akuffo, K.O.; Moran, R.; Thurnham, D.I.; Dennison, J.; Meagher, K.A.; Beatty, S.
Serum and macular response to carotenoid-enriched egg supplementation in human subjects: The egg xanthophyll intervention
clinical trial (EXIT). Br. J. Nutr. 2017, 117, 108–123. [CrossRef] [PubMed]
45. Obana, A.; Tanito, M.; Gohto, Y.; Okazaki, S.; Gellermann, W.; Bernstein, P.S. Changes in macular pigment optical density and
serum lutein concentration in Japanese subjects taking two different lutein supplements. PLoS ONE 2015, 10, e0139257. [CrossRef]
46. Bone, R.A.; Davey, P.G.; Roman, B.O.; Evans, D.W. Efficacy of commercially available nutritional supplements: Analysis of serum
uptake, macular pigment optical density and visual functional response. Nutrients 2020, 12, 1321. [CrossRef]
47. Chung, H.-Y.; Rasmussen, H.M.; Johnson, E.J. Human nutrition and metabolism lutein bioavailability is higher from lutein-
enriched eggs than from supplements and spinach. J. Nutr. 2004, 134, 1887–1893. [CrossRef] [PubMed]
48. DiSilvestro, R.A.; Thomas, S.; Harrison, E.; Epitropoulos, A. A pilot comparison of phospolipidated lutein to conventional lutein
for effects on plasma lutein concentrations in adult people. Nutr. J. 2015, 14, 104. [CrossRef]
49. Kim, J.E.; Gordon, S.L.; Ferruzzi, M.G.; Campbell, W.W. Effects of egg consumption on carotenoid absorption from co-consumed,
raw vegetables. Am. J. Clin. Nutr. 2015, 102, 75–83. [CrossRef]
50. Couasnon, D.; Cobast, E.; Herve, A.; Hazif, E.L.E.; Legrand, A.B. Prévention de la dégénérescence maculaire liée à l’âge. J. Pharm.
Clin. 2010, 29, 61–87.
51. Astorg, P.; Arnault, N.; Czernichow, S.; Noisette, N.; Galan, P.; Hercberg, S. Dietary intakes and food sources of n-6 and n-3 PUFA
in French adult men and women. Lipids 2004, 39, 527–535. [CrossRef]
52. Korobelnik, J.-F.; Rougier, M.-B.; Delyfer, M.-N.; Bron, A.; Merle, B.M.J.; Savel, H.; Chêne, G.; Delcourt, C.; Creuzot-Garcher, C.
Effect of dietary supplementation with Lutein, Zeaxanthin, andω-3 on macular pigment. JAMA Ophthalmol. 2017, 135, 1259–1266.
[CrossRef]
Nutrients 2021, 13, 3347 17 of 17
53. Chew, E.Y.; Clemons, T.E.; Sangiovanni, J.P.; Danis, R.P.; Ferris, F.L.; Elman, M.J.; Antoszyk, A.N.; Ruby, A.J.; Orth, D.; Bressler,
S.B.; et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2
report no. 3. JAMA Ophthalmol. 2014, 132, 142–149. [CrossRef]
54. Gopinath, B.; Flood, V.M.; Wang, J.J.; Burlutsky, G.; Mitchell, P. Lower dairy products and calcium intake is associated with
adverse retinal vascular changes in older adults. Nutr. Metab. Cardiovasc. Dis. 2014, 24, 155–161. [CrossRef] [PubMed]
55. Fujimura, S.; Ueda, K.; Nomura, Y.; Yanagi, Y. Preliminary analysis of the relationship between serum lutein and zeaxanthin
levels and macular pigment optical density. Clin. Ophthalmol. 2016, 10, 2149–2155. [CrossRef]
56. Olmedilla-Alonso, B.; Beltrán-de-Miguel, B.; Estévez-Santiago, R.; Cuadrado-Vives, C. Markers of lutein and zeaxanthin status in
two age groups of men and women: Dietary intake, serum concentrations, lipid profile and macular pigment optical density.
Nutr. J. 2014, 13, 52. [CrossRef] [PubMed]
57. Bone, R.A.; Landrum, J.T. Dose-dependent response of serum lutein and macular pigment optical density to supplementation
with lutein esters. Arch. Biochem. Biophys. 2010, 504, 50–55. [CrossRef]
58. Sandberg, M.A.; Johnson, E.J.; Berson, E.L. The relationship of macular pigment optical density to serum lutein in retinitis
pigmentosa. Investig. Opthalmol. Vis. Sci. 2010, 51, 1086–1091. [CrossRef] [PubMed]
59. Bernstein, P.S.; Ahmed, F.; Liu, A.; Allman, S.; Sheng, X.; Sharifzadeh, M.; Ermakov, I.; Gellermann, W. Macular pigment imaging
in AREDS2 participants: An ancillary study of AREDS2 subjects enrolled at the moran eye center. Investig. Opthalmol. Vis. Sci.
2012, 53, 6178–6186. [CrossRef] [PubMed]
60. Kannel, W.B.; Castelli, W.P.; McNamara, P.M. Serum lipid fractions and risk of coronary heart disease. The Framingham study.
Minn. Med. 1969, 52, 1225–1230.
61. Nakamura, Y.; Iso, H.; Kita, Y.; Ueshima, H.; Okada, K.; Konishi, M.; Inoue, M.; Tsugane, S. Egg consumption, serum total
cholesterol concentrations and coronary heart disease incidence: Japan Public Health Center-based prospective study. Br. J. Nutr.
2006, 96, 921–928. [CrossRef] [PubMed]
62. Baumgartner, S.; Kelly, E.R.; van der Made, S.; Berendschot, T.T.; Husche, C.; Lütjohann, D.; Plat, J. The influence of consuming an
egg or an egg-yolk buttermilk drink for 12 wk on serum lipids, inflammation, and liver function markers in human volunteers.
Nutrition 2013, 29, 1237–1244. [CrossRef]
63. Ohman, M.; Akerfeldt, T.; Nilsson, I.; Rosen, C.; Hansson, L.-O.; Carlsson, M.; Larsson, A. Biochemical effects of consumption of
eggs containing omega-3 polyunsaturated fatty acids. Upsala J. Med. Sci. 2008, 113, 315–324. [CrossRef] [PubMed]
64. Alexander, D.D.; Miller, P.E.; Vargas, A.J.; Weed, D.L.; Cohen, S.S. Meta-analysis of egg consumption and risk of coronary heart
disease and stroke. J. Am. Coll. Nutr. 2016, 35, 704–716. [CrossRef]
65. Teunissen-Beekman, K.F.; Dopheide, J.; Geleijnse, J.M.; Bakker, S.J.; Brink, E.J.; de Leeuw, P.W.; van Baak, M.A. Protein
supplementation lowers blood pressure in overweight adults: Effect of dietary proteins on blood pressure (PROPRES), a
randomized trial. Am. J. Clin. Nutr. 2012, 95, 966–971. [CrossRef]
66. Robinson, J.G.; Stone, N.J. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am. J. Cardiol. 2006, 98, 39–49.
[CrossRef]
67. Ma, L.; Liu, R.; Du, J.; Liu, T.; Wu, S.; Liu, X. Lutein, Zeaxanthin and meso-zeaxanthin supplementation associated with macular
pigment optical density. Nutrients 2016, 8, 426. [CrossRef]
68. Delori, F.C.; Goger, D.G.; Hammond, B.R.; Snodderly, D.M.; Burns, S.A. Macular pigment density measured by autofluorescence
spectrometry: Comparison with reflectometry and heterochromatic flicker photometry. J. Opt. Soc. Am. A 2001, 18, 1212–1230.
[CrossRef] [PubMed]
69. Merle, B.M.J.; Buaud, B.; Korobelnik, J.-F.; Bron, A.; Delyfer, M.-N.; Rougier, M.-B.; Savel, H.; Vaysse, C.; Creuzot-Garcher, C.;
Delcourt, C. Plasma long-chain omega-3 polyunsaturated fatty acids and macular pigment in subjects with family history of
age-related macular degeneration: The Limpia study. Acta Ophthalmol. 2017, 95, e763–e769. [CrossRef] [PubMed]
70. Dennison, J.L.; Stack, J.; Beatty, S.; Nolan, J.M. Concordance of macular pigment measurements obtained using customized
heterochromatic flicker photometry, dual-wavelength autofluorescence, and single-wavelength reflectance. Exp. Eye Res. 2013,
116, 190–198. [CrossRef]
71. Creuzot-Garcher, C.; Koehrer, P.; Picot, C.; Aho, S.; Bron, A.M. Comparison of two methods to measure macular pigment optical
density in healthy subjects. Investig. Opthalmol. Vis. Sci. 2014, 55, 2941–2946. [CrossRef] [PubMed]
72. Bernstein, P.S.; Li, B.; Vachali, P.P.; Gorusupudi, A.; Shyam, R.; Henriksen, B.S.; Nolan, J.M. Lutein, zeaxanthin, and meso-
zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease. Prog.
Retin. Eye Res. 2015, 50, 34–66. [CrossRef] [PubMed]
